Algahtani 2015.

Study characteristics
Methods	RCT: NCT01321788
Participants	300 women were randomised Setting: Riyadh, Saudi Arabia. Dates of the study: not reported. Inclusion criteria: women aged 18 to 35 years, undergoing caesarean section. Exclusion criteria: not reported in abstracts, but detailed in trial registration as being at high risk for thromboembolism (any 1 of the following): aged > 35 years, obese, parity > 4, gross varicose veins, current infection, pre‐eclampsia, immobility prior to surgery, major current disease (including heart of lung disease, cancer, inflammatory bowel disease and nephrotic syndrome), extended major pelvic or abdominal surgery, with a family history of VTE, or a history of superficial phlebitis); more than 36 hours since birth, with need for anticoagulation (women with confirmed thrombophilia, with paralysis of lower limbs, with a personal history of VTE, with antiphospholipid antibody syndrome, or mechanical heart valves), and no contraindications to heparin therapy.
Interventions	Group 1 (n = 100): LMWH (tinzaparin), 4500 IU subcutaneously once daily, starting from 12 to 24 hours after caesarean section, for 2 weeks. Group 2 (n = 200): placebo, once daily, timing as above. All women: received non‐pharmacological prophylaxis using graduated compression stockings.
Outcomes	Review outcomes reported: maternal death; symptomatic DVT. Other outcomes reported: none
Notes	Information extracted from conference abstracts. Number randomised somewhat unclear, as there appears to be an error in the abstract, which reports that 200 women consented, and also that there were 100 and 200 women in the intervention and comparison groups, respectively.   Unable to find a contact email address for author to clarify. Funding sources: not reported. Declarations of interest: not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Subjects were randomized into two groups..."
Allocation concealment (selection bias)	Unclear risk	Insufficient information to determine.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to determine (despite reported use of a placebo).
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to determine.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to determine.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to determine. Additionally, "minor and major bleeding events" reported as an outcome of interest in abstract methods, but results not reported for this outcome; trial registration also specifies PE and thrombocytopenia as outcomes of interest, and these outcomes are not reported in the abstracts reporting this study.
Other bias	Unclear risk	Insufficient information to determine.